Recent studies show that patients with the most serious forms of the coronavirus had high levels of IL-6, a common inflammatory cytokine, which MediSieve has previously encountered while researching sepsis and cytokine storms.

Finding a way to selectively and rapidly target and remove IL-6 from COVID-19 patients’ bloodstream could be extremely beneficial.

Currently, the majority of severe COVID-19 patients are treated with immunoblockers or immunosuppressants. While still effective treatments, their most dangerous drawback is that the suppressants stay in the bloodstream, leaving patients immunsupressed while fighting the infection.

Broad risk groups

Immune deficient Inpatients


Over 70s

Significant worldwide burden

26m confirmed cases
850k deaths

High morbidity

Respiratory distress


Long patient care

Second wave threat

120k hospital deaths
estimated in the UK

By focusing specifically on IL-6 MediSieve can rapidly bring a product to market to alleviate the cytokine storm and hyperimmune reaction as well as the secondary sepsis that is the cause of significant mortality in COVID-19 patients. In vitro data suggest that adult IL-6 levels could be reduced by 80% in 4 hours.

Latest News

Job Posting: Quality Associate

Job Posting: Quality Associate
May 05, 2021

Job Title: Quality Associate Reports to:  Head of Engineering and Quality Start Date:  ASAP Hours of Work:  37.5 hours per week (full-time, 6-month probation) Salary:  £28-33k PA Closing Date:  End of December 2020 Please send your CV and a cover letter expl...
MediSieve selected for the London & Partners’ Business Growth Programme

MediSieve selected for the London & Partners’ Business Growth Programme
June 05, 2020

MediSieve was accepted onto the London & Partners’ Business Growth Programme! The free, three-month programme is giving London-based companies the tools they need to survive and thrive during these challenging times - from mentorship and account management, to expert advice and new business opportu...